Cachexia: A preventable comorbidity of cancer. A T.A.R.G.E.T. approach

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 2, 2015, Pages 251-259

  Muscaritoli, Maurizio ^a   Molfino, Alessio ^a   Lucia, Simone ^a   Rossi Fanelli, Filippo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cachexia; Cancer; Comorbidity; Prevention; Therapy

Indexed keywords

ANAMORELIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BORTEZOMIB; BRANCHED CHAIN AMINO ACID; CANNABINOID; CELECOXIB; CLAZAKIZUMAB; CYCLOOXYGENASE 2 INHIBITOR; ENOBOSARM; GESTAGEN; GHRELIN; ICOSAPENTAENOIC ACID; INFLIXIMAB; INSULIN; LENALIDOMIDE; MEGESTROL ACETATE; MT 102; OLANZAPINE; OXANDROLONE; PEPTIDE NUCLEIC ACID; SELECTIVE ANDROGEN RECEPTOR MODULATOR; THALIDOMIDE; UNCLASSIFIED DRUG;

AWARENESS; CACHEXIA; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; COMORBIDITY; EXERCISE; GENETICS; HUMAN; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); RECOGNITION; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TEACHING; ATTITUDE TO HEALTH; COMPLICATION; GENETIC PREDISPOSITION; NEOPLASMS; PATIENT EDUCATION;

CACHEXIA; COMORBIDITY; EXERCISE; GENETIC PREDISPOSITION TO DISEASE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; NEOPLASMS; PATIENT EDUCATION AS TOPIC;

EID: 84926095923     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.10.014     Document Type: Review

References (71)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62(1):10-29.
2. Siegel R., DeSantis C., Virgo K., et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012, 62(4):220-241. Epub 2012 Jun 14. 10.3322/caac.21149.
3. Rock C.L., Doyle C., Demark-Wahnefried W., et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012, 62(4):243-274.
4. Muscaritoli M., Bossola M., Aversa Z., Bellantone R., Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006, 42(January (1)):31-41.
5. Lucia S., Esposito M., Rossi Fanelli F., Muscaritoli M. Cancer cachexia: from molecular mechanisms to patient's care. Crit Rev Oncog 2012, 17(3):315-321.
6. Aapro M., Arends J., Bozzetti F., et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 2014, May, [Epub ahead of print].
7. Fearon K., Strasser F., Anker S.D., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12(May (5)):489-495. Epub 2011 Feb 4. 10.1016/S1470-2045(10)70218-7.
8. Evans W.J., Morley J.E., Argilés J., et al. Cachexia: a new definition. Clin Nutr 2008, 27(December (6)):793-799. 10.1016/j.clnu.2008.06.013.
9. Muscaritoli M., Anker S.D., Argilés J., et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr 2010, 29(April (2)):154-159. 10.1016/j.clnu.2009.12.004.
10. von Haehling S., Anker S.D. Cachexia as major underestimated unmet medical need: facts and numbers. Int J Cardiol 2012, 161(November (3)):121-123. 10.1016/j.ijcard.2012.09.213.
11. Muscaritoli M., Costelli P., Aversa Z., Bonetto A., Baccino F.M., Rossi Fanelli F. New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway'. Asia Pac J Clin Nutr 2008, 17(Suppl. 1):387-390. [Review].
12. Muscaritoli M., Molfino A., Gioia G., Laviano A., Rossi Fanelli F. The "parallel pathway": a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med 2011, 6(April (2)):105-112. 10.1007/s11739-010-0426-1.
13. Blum D., Stene G., Solheim T., et al. Validation of the consensus-definition for cancer cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 2014, 25:1635-1642.
14. Blauwhoff-Buskermolen S., de van der Schueren M.A., Verheul H.M., Langius J.A. 'Pre-cachexia': a non-existing phenomenon in cancer?. Ann Oncol 2014, 25:1668-1669.
15. Paccagnella A., Morello M., Da Mosto M.C., et al. Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy. Support Care Cancer 2010, 18(July (7)):837-845.
16. Hughes B.G., Jain V.K., Brown T., et al. Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution. Head Neck 2013, 35(March (3)):436-442. 10.1002/hed.22992.
17. Huhmann M.B., August D.A. Nutrition support in surgical oncology. Nutr Clin Pract 2009, 24(August-September (4)):520-526. 10.1177/0884533609335375.
18. van der Meij B.S., Langius J.A., Smit E.F., et al. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr 2010, 140(October 10):1774-1780. 10.3945/jn.110.121202.
19. Chen Y., Liu B.L., Shang B., et al. Nutrition support in surgical patients with colorectal cancer. World J Gastroenterol 2011, 17(April (13)):1779-1786. 10.3748/wjg.v17.i13.1779.
20. Capuano G., Grosso A., Gentile P.C., et al. Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy. Head Neck 2008, 30(April (4)):503-508.
21. Silander E., Jacobsson I., Bertéus-Forslund H., Hammerlid E. Energy intake and sources of nutritional support in patients with head and neck cancer-a randomised longitudinal study. Eur J Clin Nutr 2013, 67(January (1)):47-52. 10.1038/ejcn.2012.172.
22. Ross P.J., Ashley S., Norton A., et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br J Cancer 2004, 90(May (10)):1905-1911.
23. van der Meij B.S., Langius J.A., Spreeuwenberg M.D., et al. Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr 2012, 66(March (3)):399-404. 10.1038/ejcn.2011.214.
24. Read J.A., Beale P.J., Volker D.H., Smith N., Childs A., Clarke S.J. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer 2007, 15(March (3)):301-307.
25. Ryan A.M., Reynolds J.V., Healy L., et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg 2009, 249(March (3)):355-363. 10.1097/SLA.0b013e31819a4789.
26. Fried L.P., Ferrucci L., Darer J., Williamson J.D., Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004, 59(March (3)):255-263.
27. Land L.H., Dalton S.O., Jensen M.B., Ewertz M. Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008. Breast Cancer Res Treat 2012, 131(February (3)):1013-1020.
28. Lee L., Cheung W.Y., Atkinson E., Krzyzanowska M.K. Impact of comorbidity on chemotherapy use and outcome in solid tumors: a systematic review. J Clin Oncol 2011, 29(1):106-117.
29. Louwman W.J., Janssen-Heijnen M.L.G., Houterman S., et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 2005, 41:779-785.
30. Groome P.A., Rohland S.L., Siemens D.R., Brundage M.D., Heaton J., Mackillop W.J. Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. Cancer 2011, 117(September (17)):3943-3952. 10.1002/cncr.25984.
31. Asmis T.R., Ding K., Seymour L., et al. National Cancer Institute of Canada Clinical Trials Group. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008, 26(January (1)):54-59.
32. Sarfati D., Tan L., Blakely T., Pearce N. Comorbidity among patients with colon cancer in New Zealand. N Z Med J 2011, 124(July (1338)):76-88.
33. Paleri V., Wight R.G., Silver C.E., et al. Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 2010, 46(October (10)):712-719.
34. Truong P.T., Kader H.A., Lacy B., et al. The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol 2005, 28(April (2)):157-164.
35. Maas H.A., Kruitwagen R.F., Lemmens V.E., Goey S.H., Janssen-Heijnen M.L. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 2005, 97(April (1)):104-109.
36. van Weel C., Schellevis F.G. Comorbidity and guidelines: conflicting interests. Lancet 2006, 367(February (9510)):550-551.
37. Mowe M., Bosaeus I., Rasmussen H.H., et al. Scandinavian Nutrition Group Insufficient nutritional knowledge among health care workers?. Clin Nutr 2008, 27(April (2)):196-202. 10.1016/j.clnu.2007.10.014.
38. Adams K.M., Lindell K.C., Kohlmeier M., Zeisel S.H. Status of nutrition education in medical schools. Am J Clin Nutr 2006, 83(April (4)):941S-944S.
39. Orimo H., Ueno T., Yoshida H., Sone H., Tanaka A., Itakura H. Nutrition education in Japanese medical schools: a follow-up survey. Asia Pac J Clin Nutr 2013, 22(1):144-149. 10.6133/apjcn.2013.22.1.13.
40. Beck A.M., Balknäs U.N., Fürst P., et al. Council of Europe (the Committee of Experts on Nutrition Food Safety and Consumer Health of the Partial Agreement in the Social and Public Health Field). Food and nutritional care in hospitals: how to prevent undernutrition - report and guidelines from the Council of Europe. Clin Nutr 2001, 20(October (5)):455-460.
41. Barendregt K., Soeters P.B., Allison S.P. Influence of malnutrition on physiological function. Basics in clinical nutrition 2004, 18-20. Galen. 3rd ed. L. Sobotka (Ed.).
42. Beattie E., O'Reilly M., Strange E., Franklin S., Isenring E. How much do residential aged care staff members know about the nutritional needs of residents?. Int J Older People Nurs 2013, February, 10.1111/opn.12016.
43. Spiro A., Baldwin C., Patterson A., Thomas J., Andreyev H.J. The views and practice of oncologists towards nutritional support in patients receiving chemotherapy. Br J Cancer 2006, 95(August (4)):431-434.
44. Deans C., Rose-Zerilli M., Wigmore S., et al. Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol 2007, 14(February (2)):329-339.
45. Solheim T.S., Fayers P.M., Fladvad T., et al. Is there a genetic cause of appetite loss? An explorative study in 1,853 cancer patients. J Cachexia Sarcopenia Muscle 2012, 3(September (3)):191-198. 10.1007/s13539-012-0064-8.
46. Punzi T., Fabris A., Morucci G., et al. C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients. Mol Diagn Ther 2012, 16(April (2)):115-124. 10.2165/11632380-000000000-00000.
47. Tan B.H., Fladvad T., Braun T.P., et al. European Palliative Care Research Collaborative P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol Med 2012, 4(June (6)):462-471. 10.1002/emmm.201200231.
48. Guthrie G.J., Roxburgh C.S., Richards C.H., Horgan P.G., McMillan D.C. Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. Br J Cancer 2013, 109(July (1)):131-137. 10.1038/bjc.2013.291.
49. Tan B.H., Ross J.A., Kaasa S., Skorpen F., Fearon K.C. European Palliative Care Research Collaborative Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review. J Genet 2011, 90(April (1)):165-177.
50. Deans D.A., Tan B.H., Ross J.A., et al. Cancer cachexia is associated with the IL10-1082 gene promoter polymorphism in patients with gastroesophageal malignancy. Am J Clin Nutr 2009, 89(April (4)):1164-1172. 10.3945/ajcn.2008.27025.
51. Mantovani G., Madeddu C., Macciò A. Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Drug Des Devel Ther 2013, 7(August):645-656. 10.2147/DDDT.S39771.
52. Rogers E.S., MacLeod R.D., Stewart J., Bird S.P., Keogh J.W. A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study. BMC Cancer 2011, 11(November):493.
53. Murphy R.A., Yeung E., Mazurak V.C., Mourtzakis M. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer 2011, 105(November (10)):1469-1473. 10.1038/bjc.2011.391.
54. Ries A., Trottenberg P., Elsner F., et al. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: An EPCRC cachexia guidelines project. Palliat Med 2012, 26(June (4)):294-304. 10.1177/0269216311418709.
55. Thompson R. Preventing cancer: the role of food, nutrition and physical activity. J Fam Health Care 2010, 20(3):100-102.
56. Mishra S.I., Scherer R.W., Snyder C., Geigle P.M., Berlanstein D.R., Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012, 8(August):CD008465. [Review]. 10.1002/14651858.CD008465.pub2.
57. Maddocks M., Murton A.J., Wilcock A. Therapeutic exercise in cancer cachexia. Crit Rev Oncog 2012, 17(3):285-292.
58. Lira F.S., Yamashita A.S., Rosa J.C., et al. Exercise training decreases adipose tissue inflammation in cachectic rats. Horm Metab Res 2012, 44(February (2)):91-98. 10.1055/s-0031-1299694.
59. Gould D.W., Lahart I., Carmichael A.R., Koutedakis Y., Metsios G.S. Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia Muscle 2013, 4(June (2)):111-124. 10.1007/s13539-012-0096-0.
60. Subirats Bayego E., Subirats Vila G., Soteras Martínez I. Exercise prescription: indications, dosage and side effects. Med Clin (Barc) 2012, 138(January (1)):18-24. 10.1016/j.medcli.2010.12.008.
61. Coss C.C., Bohl C.E., Dalton J.T. Cancer cachexia therapy: a key weapon in the fight against cancer. Curr Opin Clin Nutr Metab Care 2011, 14(May (3)):268-273. [Review].
62. Gullett N.P., Mazurak V.C., Hebbar G., Ziegler T.R. Nutritional interventions for cancer-induced cachexia. Curr Probl Cancer 2011, 35(March-April (2)):58-90.
63. Mantovani G., Macciò A., Madeddu C., et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010, 15(2):200-211.
64. Madeddu C., Dessì M., Panzone F., et al. Randomized phase III clinical trial of a combined treatment with carnitine+celecoxib±megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 2012, 31(April (2)):176-182. 10.1016/j.clnu.2011.10.005.
65. Muscaritoli M., Molfino A., Laviano A., Rasio D., Rossi Fanelli F. Parenteral nutrition in advanced cancer patients. Crit Rev Oncol Hematol 2012, 84(October (1)):26-36.
66. Ravasco P., Monteiro-Grillo I., Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am J Clin Nutr 2012, 96(December (6)):1346-1353. 10.3945/ajcn.111.018838.
67. Egan M.Y., McEwen S., Sikora L., Chasen M., Fitch M., Eldred S. Rehabilitation following cancer treatment. Disabil Rehabil 2013, 35:2245-2258.
68. Arends J., Bodoky G., Bozzetti F., et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr 2006, 25(April (2)):245-259.
69. Bozzetti F., Arends J., Lundholm K., et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr 2009, 28(August (4)):445-454. 10.1016/j.clnu.2009.04.011.
70. Tazi E., Errihani H. Treatment of cachexia in oncology. Indian J Palliat Care 2010, 16(September (3)):129-137. 10.4103/0973-1075.73644.
71. http://www.clinicaltrials.gov/.